Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: jj_ who wrote (4305)	7/13/2001 8:41:11 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

genomics is the 4th pillar of the first wave........ Wow. I didn't know. I'll rush right out and buy some genomics companies. Do you have any favorites? and hgsi own most of the gene pattens For those who don't know it, gene pattens are the little securing devices that we use to carry genes around the lab. HGSI probably does have a bunch of them, but..... even if they're the type with the convenient handle and little puffy balls at the 3' end, does that justify a research premium of $4.4 billion?

To: jj_ who wrote (4305)	7/26/2001 1:00:00 AM
From: jj_	Read Replies (1) \| Respond to of 52153

dallasnews.com Wednesday \| July 25, 2001 Genetically engineered drug promising against leukemia 07/26/2001 Associated Press BOSTON – A genetically engineered drug shows great early promise in tracking down and killing a rare leukemia, raising doctors' hopes in the long quest for a magic bullet against cancer. Eleven of the 16 patients treated in a study of the drug were left with no readily detectable trace of the disease. The experimental drug relies on a piece of antibody from a mouse's immune system to latch onto the cancer cells while shunning normal cells. A bacterial poison fused to the antibody is carried inside the cancer cells and kills them. Doctors have long tested mouse antibodies as drugs. Researchers said this drug and similar ones may eventually prove useful for other types of cancer. Researchers at the National Cancer Institute in Bethesda, Md., developed and tested the drug, a so-called immunotoxin known as BL22, on 16 patients with hairy cell leukemia untreatable by the usual chemotherapy. Their study appears in Thursday's edition of The New England Journal of Medicine.